title: [A case of peritoneal dissemination that exhibited a complete response to systemic chemotherapy following the resection of primary colon cancer].
abstract: In June 2010, a 62-year-old man underwent right hemicolectomy with transverse colostomy for advanced ascending colon cancer with peritoneal dissemination(pSE, pN3H0P3M0, fStage IV, R2). One month after surgery, systemic chemotherapy (combination regimen of oxaliplatin injection and S-1 per os; SOX regimen) was introduced for the residual lesion. After completing 4 courses of the SOX regimen, peritoneal dissemination was not detected by abdominal computed tomography. In the same month, laparotomy was performed to close the temporary stoma, in which the lack of peritoneal dissemination was confirmed. After the stoma was closed, although no chemotherapy was administered because of patient preference, he has been free from relapse of the peritoneal dissemination, according to his latest follow-up examinations in June 2012. In this case, resection of the primary lesion immediately followed by a short period of systemic chemotherapy resulted in good control of peritoneal dissemination. Because the effect of these therapies allowed him to undergo stoma closure and to refuse further chemotherapy, he has been able to maintain his quality of life. In cases of reduction surgery for advanced colorectal cancer with unresectable peritoneal dissemination, a minimal resection including the primary lesion to avoid perioperative complications, which could permit the immediate start of systemic chemotherapy, could result in good control of peritoneal dissemination.
authors.affiliation: Dept. of Surgery, Suita Municipal Hospital, Japan.
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Kohei
authors.initials: K
authors.lastname: Murata
authors.forename: Yuma
authors.initials: Y
authors.lastname: Wada
authors.forename: Ryo
authors.initials: R
authors.lastname: Kato
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Makino
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Ohwada
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nishigaki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Okada
authors.forename: Tetsu
authors.initials: T
authors.lastname: Yanagisawa
authors.forename: Chikara
authors.initials: C
authors.lastname: Ebisui
authors.forename: Hideoki
authors.initials: H
authors.lastname: Yokouchi
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Kinuta
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003125:Colostomy; D003131:Combined Modality Therapy; D004338:Drug Combinations; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D011788:Quality of Life; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid